Losartan
Arbli, Cozaar, Hyzaar, Losartan Potassium (losartan) is a small molecule pharmaceutical. Losartan was first approved as Cozaar on 1995-04-14. It is used to treat diabetic nephropathies, heart failure, hypertension, left ventricular dysfunction, and left ventricular hypertrophy in the USA. The pharmaceutical is active against type-1 angiotensin II receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| arbli | New Drug Application | 2025-03-20 |
| cozaar | New Drug Application | 2025-06-20 |
| hyzaar | New Drug Application | 2025-10-02 |
| losartan | ANDA | 2018-02-15 |
| losartan pot/hctz | ANDA | 2019-08-02 |
| losartan potassium | ANDA | 2025-10-03 |
| losartan potassium and hydrochlorothiazide | ANDA | 2025-09-04 |
| losartan potassium and hydrochlorothiazide | ANDA | 2025-10-02 |
| losartan potassium and hydrochlorothiazide losartan potassium hctz | ANDA | 2019-10-14 |
| losartan potassium losartan potassium | ANDA | 2025-07-28 |
Show 9 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA01: Losartan
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA01: Losartan and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DB06: Losartan and amlodipine
HCPCS
No data
Clinical
Clinical Trials
445 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 1 | 7 | 2 | 2 | 13 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | 1 | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | 1 | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | 1 | — | 1 |
| Emphysema | D004646 | EFO_0000464 | J43 | — | — | — | 1 | — | 1 |
| Chronic bronchitis | D029481 | — | J42 | — | — | — | 1 | — | 1 |
| Smoking | D012907 | EFO_0004318 | — | — | — | — | 1 | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
| Hyperglycemia | D006943 | — | R73.9 | — | — | — | 1 | — | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Essential hypertension | D000075222 | — | I10 | — | — | 1 | — | — | 1 |
| Marfan syndrome | D008382 | Orphanet_558 | Q87.4 | — | — | 1 | — | — | 1 |
| Camurati-engelmann syndrome | D003966 | Orphanet_1328 | Q78.3 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Retinal diseases | D012164 | — | H35.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 1 | — | — | — | — | 1 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Losartan |
| INN | losartan |
| Description | Losartan is a biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an endothelin receptor antagonist and an anti-arrhythmia drug. It is a biphenylyltetrazole and a member of imidazoles. It is a conjugate acid of a losartan(1-). |
| Classification | Small molecule |
| Drug class | angiotensin II receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 114798-26-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL191 |
| ChEBI ID | 6541 |
| PubChem CID | 3961 |
| DrugBank | DB00678 |
| UNII ID | JMS50MPO89 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CYP2C9
CYP2C9
Organism
Homo sapiens
Gene name
CYP2C9
Gene synonyms
CYP2C10
NCBI Gene ID
Protein name
cytochrome P450 2C9
Protein synonyms
(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, Cholesterol 25-hydroxylase, CYPIIC9, cytochrome P-450 S-mephenytoin 4-hydroxylase, Cytochrome P-450MP, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 PB-1, cytochrome P450, family 2, subfamily C, polypeptide 9, flavoprotein-linked monooxygenase, microsomal monooxygenase, S-mephenytoin 4-hydroxylase, xenobiotic monooxygenase
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Losartan
+
Hydrochlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Losartan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 29,817 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arbli, Cozaar, Hyzaar, Losartan, Losartan potassium, Losartan potassium and hydrochlorothiazide, Losartan potassium and hydrochlorothiazide, Losartan potassium and hydrochlorothiazide losartan potassium hctz, Losartan potassium losartan potassium, Losartan potassium losortan potassium, Losartan potassium tablets, 100 mg, Losartan potassium tablets, 100 mg losartan potassium tablets, 25 mg losartan potassium tablets, 50 mg, Losartan potassium tablets, 25 mg, Losartan potassium tablets, 50 mg, Losartan potatssium, Losatan potassium, Losortan potassium, Tradename
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
141,752 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use